HOME >> BIOLOGY >> NEWS
Studies of rare blood syndrome yield novel route to cancer

By carefully studying why a rare blood disorder responds to the anti-cancer drug Gleevec, researchers have discovered an entirely new mechanism that generates cancer-causing genes.

The study, published in the March 27, 2003, issue of the New England Journal of Medicine, shows that Gleevec is an effective treatment for hypereosinophilic syndrome (HES), a blood disorder that is nearly always fatal. According to the researchers, their studies suggest that HES should be reclassified by the World Health Organization from its current "gray-area" status as a "syndrome" to a form of cancer.

Senior authors of the article were D. Gary Gilliland, a Howard Hughes Medical Institute investigator at Brigham and Women's Hospital and Harvard Medical School, and Richard Stone at the Dana-Farber Cancer Institute (DFCI). Joint first authors on the paper were Jan Cools, a postdoctoral fellow in Gilliland's laboratory, and Daniel DeAngelo, who is also at DFCI and an instructor at Harvard Medical School.

HES is caused by overproliferation of a type of white blood cells called eosinophils. Physicians treat the syndrome with a combination of drugs and chemotherapy, said Gilliland, but eventually, the assault of eosinophils damages major organs, and causes the heart or lungs to fail, and ultimately results in death of most patients.

Recently, however, hints that the disorder might respond to Gleevec began to crop up in the medical literature. "There was a report of a single case of an HES patient treated with Gleevec and had what was described as a miraculous response," said Gilliland. "This anecdotal report was substantiated by a group of investigators that reported successful treatment in 4 of 5 additional HES patients, reported in the The Lancet (a British medical journal) last year.

Gleevec works by inhibiting enzymes called tyrosine kinases. When the activity of
'"/>

Contact: Jim Keeley
keeleyj@hhmi.org
301-215-8858
Howard Hughes Medical Institute
26-Mar-2003


Page: 1 2 3 4

Related biology news :

1. Monkey business: Studies show tiny callimicos have unusual characteristics
2. Studies show success of Mectizan partnerships
3. Studies offer new insight into HIV vaccine development
4. Studies suggest brain injury results from developmental exposure to alcohol, anesthesia, and lead
5. Studies show preventive value of food supplements
6. Studies probe rapid evolution of Chinese tallow trees
7. Studies dispute ultraviolet effect on amphibian population declines
8. Studies of spiders silk reveal unusual strength
9. Studies of genes in mice and common worm may accelerate research on blood diseases, cancers
10. Studies offer data on potential impact of Reminyl on caregiver burden in Alzheimers disease
11. Studies: Floyd, other major hurricanes of 99 caused significant changes in nations largest lagoonal estuary

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:6/13/2020)... ... June 11, 2020 , ... Bode Technology (Bode), ... forensic genealogy team. Bode’s Forensic Genealogy Service (FGS) continues to deliver ... analysis methods. The team has added experienced genealogists, each having over a decade ...
(Date:6/11/2020)... ... June 09, 2020 , ... Superior Controls, Inc. , an E Technologies ... for the life sciences industry, is pleased to announce the recent hiring of Ray ... company’s Seabrook, New Hampshire office. In his new role, Boudreau will use his ...
(Date:6/5/2020)... ... June 04, 2020 , ... “Although we are disappointed to have to ... attendees, staff, and the public. We remain committed to creating a global platform ... virtually,” said Julie Sutcliffe, President of WMIS. , The abstract deadline ...
Breaking Biology News(10 mins):
(Date:7/1/2020)... WESTMINSTER, Colo. (PRWEB) , ... ... ... providers of expert tissue data insights, today announced that the launch of ... PD-L1 results along with data about the tumor microenvironment (TME). , “Flagship’s ...
(Date:6/28/2020)... ... June 25, 2020 , ... Lumeda ... treating cancer, today announced the company has entered a license agreement with Roswell ... provides Lumeda globally exclusive rights to Roswell Park intellectual property surrounding a novel ...
(Date:6/23/2020)... ... June 23, 2020 , ... DeCurtis Corporation, the ... today that Derek Fournier has been appointed CEO and President. Founder and former ... immediately. , “DeCurtis Corporation has been on an incredible journey for the ...
(Date:6/23/2020)... Ore. (PRWEB) , ... June 23, 2020 , ... ... of innovative CNS therapies, today announced that it has filed an Investigational New ... a Phase 2b clinical trial of its lead drug candidate NBTX-001 in patients ...
Breaking Biology Technology:
Cached News: